Pharmaceutical Industry Full of Prospects, Sales Targeted to Soar in 2026
The national pharmaceutical industry still holds opportunities for growth amidst various global economic challenges. This optimism has driven PT Phapros Tbk (PEHA) to target sales growth of over 20 per cent by 2026, after successfully recording improved financial performance over the last two years.
The pharmaceutical company, which is part of the state-owned pharmaceutical holding, recorded a net profit growth of 109% and a sales increase of 26.34% year-on-year throughout 2025. This positive trend continued into the first quarter of 2026, with net profit growth reaching 112.86% compared to the same period the previous year.
This performance was supported by a 10.17% increase in sales to Rp221.09 billion during January-March 2026, compared to Rp200.67 billion in the same period last year. At the same time, the company managed to keep increases in production costs and operating expenses under control, thereby enhancing profitability.
The President Director of PT Phapros Tbk, Intan Abdams Katoppo, stated that these achievements demonstrate the increasingly strong business foundation of the company.
“Phapros’ financial performance trend shows that the company possesses strong business fundamentals. Net profit in 2025 grew by 109%. Therefore, we are optimistic that this trend will continue until the end of this year,” she said.
To maintain growth momentum, Phapros has prepared several key strategies throughout 2026. These steps include strengthening the company’s financial position, increasing customer satisfaction, developing the product portfolio, transforming business systems and processes, and optimising human resources.
In terms of products, the company plans to launch four new products this year. One of these is a dental analgesic in powder form, designed for faster absorption by the body.
Additionally, Phapros is preparing a children’s multivitamin product to support government programmes aimed at reducing stunting rates. The product is focused on meeting children’s daily nutritional needs while supporting bone growth, brain development, dental health, and immune resistance.
Business transformation is also directed towards strengthening market share across all the company’s main segments, ranging from over-the-counter (OTC) drugs and branded generic medicines (OGB) to ethical products. The company also plans to expand its export market reach as part of its strategy to strengthen its business portfolio.
Intan emphasised that innovation and research will be crucial factors in maintaining the company’s competitiveness in an increasingly competitive pharmaceutical industry. According to her, the ability to present new products that meet societal needs will be key for Phapros to maintain growth while strengthening its position in both national and international pharmaceutical markets.
Source: jawawa.id (https://jawawa.id/newsitem/pharmaceutical-industry-full-of-prospects-sales-targeted-to-soar-in-2026-1781261459)
Originally published by Media Indonesia (https://mediaindonesia.com/ekonomi/899852/industri-farmasi-penuh-prospek-penjualan-ditargetkan-melesat-pada-2026), translated from Indonesian